Pacira BioSciences CFO on Growth, No Pain Act Impact & 2025 Outlook | 24th Annual Needham Healthcare скачать в хорошем качестве

Pacira BioSciences CFO on Growth, No Pain Act Impact & 2025 Outlook | 24th Annual Needham Healthcare

In this fireside chat from the 24th Annual Healthcare Conference, Pacira BioSciences CFO Sean Cross provides an in-depth look at the company's 2025 strategy. Topics include: Overview of Tarsus and its non-opioid pain therapies The "5 by 30" growth plan Updates on commercial products: EXPAREL, ZILRETTA, and iovera° Impact of the No Pain Act on reimbursement and sales Strategic focus on musculoskeletal pain Expansion of leadership and commercial infrastructure 2025 revenue guidance and product growth expectations Aired April 7, 2025 🔥Join my Patreon to unlock exclusive BUY signals for stocks and options! https://tinyurl.com/4uf6jpcv FREE Public Discord!   / discord   ✅If you like the latest analyst ratings and data, check out (FREE) https://bit.ly/3BM3mCk FREE Seeking Alpha Premium 7 Day trial- https://www.sahg6dtr.com/Z8ZKPB/R74QP/ ⭐⭐⭐⭐⭐𝗖𝗢𝗡𝗡𝗘𝗖𝗧 𝗪𝗜𝗧𝗛 𝗠𝗘⭐⭐⭐⭐⭐ All Links | ► https://allmylinks.com/financial-journey Twitter | ► / finjourney Disclaimer: The content on Corporate Talks is for informational and entertainment purposes only and should not be considered financial advice. We are not financial advisors, and all opinions expressed in this video are our own. Investing in stocks and other financial instruments carries risks, and you should always do your own research before making any investment decisions. Consult with a qualified financial professional before making any financial moves. Corporate Talks does not guarantee the accuracy, completeness, or reliability of any information presented. We may hold positions in the stocks or companies discussed. Always invest responsibly! Company Profile Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.